Dennis Ding
Stock Analyst at Jefferies
(n/a)
# 4,489
Out of 4,784 analysts
12
Total ratings
n/a
Success rate
-29.17%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Dennis Ding
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CRNX Crinetics Pharmaceuticals | Upgrades: Buy | $55 | $34.73 | +58.36% | 1 | Jan 22, 2025 | |
| IKT Inhibikase Therapeutics | Initiates: Buy | $8 | $2.29 | +249.34% | 1 | Nov 8, 2024 | |
| ASMB Assembly Biosciences | Upgrades: Buy | $2 → $35 | $10.62 | +229.57% | 1 | Sep 20, 2024 | |
| FOLD Amicus Therapeutics | Initiates: Buy | $18 | $8.43 | +113.52% | 1 | Sep 6, 2024 | |
| ABUS Arbutus Biopharma | Maintains: Buy | $5 → $7 | $3.50 | +100.00% | 2 | Sep 5, 2024 | |
| RXRX Recursion Pharmaceuticals | Maintains: Hold | $8 → $6 | $5.81 | +3.27% | 1 | Sep 3, 2024 | |
| LYRA Lyra Therapeutics | Downgrades: Hold | $10 → $0.5 | $0.14 | +259.97% | 1 | May 7, 2024 | |
| CARA Cara Therapeutics | Reiterates: Buy | $216 | $5.15 | +4,094.17% | 1 | Jun 27, 2023 | |
| CORT Corcept Therapeutics | Downgrades: Hold | $35 → $22 | $54.63 | -59.73% | 1 | Feb 15, 2023 | |
| NAMS NewAmsterdam Pharma Company | Initiates: Buy | $24 | $21.76 | +10.29% | 1 | Dec 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $10 | $10.38 | -3.66% | 1 | Oct 26, 2021 |
Crinetics Pharmaceuticals
Jan 22, 2025
Upgrades: Buy
Price Target: $55
Current: $34.73
Upside: +58.36%
Inhibikase Therapeutics
Nov 8, 2024
Initiates: Buy
Price Target: $8
Current: $2.29
Upside: +249.34%
Assembly Biosciences
Sep 20, 2024
Upgrades: Buy
Price Target: $2 → $35
Current: $10.62
Upside: +229.57%
Amicus Therapeutics
Sep 6, 2024
Initiates: Buy
Price Target: $18
Current: $8.43
Upside: +113.52%
Arbutus Biopharma
Sep 5, 2024
Maintains: Buy
Price Target: $5 → $7
Current: $3.50
Upside: +100.00%
Recursion Pharmaceuticals
Sep 3, 2024
Maintains: Hold
Price Target: $8 → $6
Current: $5.81
Upside: +3.27%
Lyra Therapeutics
May 7, 2024
Downgrades: Hold
Price Target: $10 → $0.5
Current: $0.14
Upside: +259.97%
Cara Therapeutics
Jun 27, 2023
Reiterates: Buy
Price Target: $216
Current: $5.15
Upside: +4,094.17%
Corcept Therapeutics
Feb 15, 2023
Downgrades: Hold
Price Target: $35 → $22
Current: $54.63
Upside: -59.73%
NewAmsterdam Pharma Company
Dec 19, 2022
Initiates: Buy
Price Target: $24
Current: $21.76
Upside: +10.29%
Oct 26, 2021
Initiates: Buy
Price Target: $10
Current: $10.38
Upside: -3.66%